June 25, 2025
Intangible Assets

Cerence Announces Second Quarter Fiscal 2025 Results; Revenue and Profitability Exceed High End of Guidance

Headlines Revenue of $78M; free cash flow of $13.1M marks fourth consecutive positive quarter Company reiterates full-year guidance for revenue and raises full-year guidance for profitability and cash flow Continued innovation and customer momentum for Cerence xUI, the company’s next-gen platform BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”),

Read More
Operating Assets

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease Negative Complete Response; 40% ORR Achieved at the 75 µg Dose Level Cemsidomide Multiple Myeloma Dose Escalation is

Read More
Operating Assets

EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as

Read More
Operating Assets

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025 Expect data readouts for DISC-0974 program in H2 2025, including

Read More
Operating Assets

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCO Full dataset from Phase 3 ICONIC-LEAD trial with icotrokinra

Read More
Operating Assets

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled and topline data are

Read More
Operating Assets

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the

Read More
Tangible Assets

FinWise Bancorp Reports First Quarter 2025 Results

– Loan Originations of $1.3 Billion – – Net Income of $3.2 Million – – Diluted Earnings Per Share of $0.23 – MURRAY, Utah, April 30, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced results for the quarter ended March 31, 2025. First

Read More
Operating Assets

Heartland Express, Inc. Reports Operating Results for the First Quarter of 2025

NORTH LIBERTY, Iowa, April 30, 2025 (GLOBE NEWSWIRE) — Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the three months ended March 31, 2025. Three months ended March 31, 2025: Operating Revenue of $219.4 million, Net Loss of $13.9 million, Basic Loss per Share of $0.18, Operating Ratio of 106.8% and 107.1% Non-GAAP

Read More
Operating Assets

Larimar Therapeutics Reports First Quarter 2025 Financial Results

FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent

Read More